Abstract 2022-RA-1607-ESGO Figure 2

Conclusion We have demonstrated that performing IDS within four weeks after NACT may be associated with better survival outcomes.

2022-RA-1611-ESGO CHECKPOINT INHIBITION IN OVARIAN CANCER WORKS – A CASE REPORT OF COMPLETE RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN A PLATINUM RESISTANT PRIMARY OVARIAN CANCER PATIENT WITH LYNCH SYNDROME

1Lukas Chinczewski, 2Felix Wilhelm Feldhaus, 3Wolfgang Daniel Schmitt, 4Elena Ioana Brăicu, 4Eva Roser, 4Jalid Sehouli.

1Department of Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 4Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany

10.1136/ijgc-2022-ESGO.756

Introduction/Background Lynch syndrome is a secondary cause for hereditary ovarian cancer after BRCA mutation. Germline mutations in the DNA-mismatch repair genes cause tumorigenesis and a high immunogenicity. Recent studies showed a promising use of immunotherapy in MMR deficient (MMRd) tumors. We present a case of a patient with LS associated OC resistant to standard therapy.

Methodology

Results A 44-year old patient was admitted to the hospital with lower abdominal pain. The patient’s history showed LS with a germline mutation in the MSH2-gene. Initial diagnostics showed a pelvic tumor mass and a highly elevated antigen 125. After debulking surgery, histopathological findings showed a high grade serous OC with a mutation in the MSH2 and MSH6-genes. Only 5 weeks after operation with no residual tumor mass a quick and significant intraabdominal progression of the disease was diagnosed. Adjuvant therapy with carboplatin and paclitaxel in a weekly course did not lead to sustainable response. An anti-PD-L1 antibody therapy with pembrolizumab was initiated. After only 2 courses of therapy the laboratory results and clinical status of the patient improved tremendously. Shortly after a complete response was detected and until today for 28 cycles immune checkpoint inhibition therapy is ongoing. The patient remains tumor free for 21 months now.

Conclusion Recent studies suggest a promising effect of checkpoint inhibition within MMRd tumors. OC on the other hand does not seem to show an overall good response to immunotherapy. The significance of germline compared to somatic mutations has not yet been investigated in prior studies sufficiently. To our knowledge, this is the first case with complete response to checkpoint inhibition in OC associated with LS. Comprehensive testing for germline mutations should be established. Regarding Lynch syndrome associated ovarian cancer, immune checkpoint inhibition is an efficient therapy in tumors nonresponsive to standard therapy.

2022-RA-1621-ESGO ROLE OF PET-CT AND CECT IN CALCULATING PREOPERATIVE PCI IN PATIENTS WITH EPITHELIAL OVARIAN CANCER

1Monica Gutierrez Martinez, 2Felix Boria, 1Lidia Sancho, 1Andrés Alcazar, 1Luís Chiva, 2Daniel Vázquez, 1Teresa Castellanos. 1Clínica Universidad de Navarra, Madrid, Spain; 2Clínica Universidad de Navarra, Clínica Universidad de Navarra, Spain

10.1136/ijgc-2022-ESGO.757

Introduction/Background The objectives are to compare the efficacy between preoperative PET/CT and CeCT findings according with the surgical findings in patients that underwent surgery for epithelial ovarian cancer treatment and to evaluate the correlation between preoperative PCI calculated in both PET/CT and CeCT with surgery.

Methodology Retrospective unicentric observational study reviewing data of 30 patients diagnosed with epithelial ovarian cancer (primary or recurrence) and operated between July 2018-February 2021 in Clínica Universidad de Navarra. Every patient underwent PET/CT and CeCT. PET/CT was independently evaluated by a nuclear medicine doctor (PET-CT) and CeCT by an expert radiologist in gynecologic malignancies. PCI in surgery was calculated by two different gynecologic oncologists. If there was any discordance between them, a media between both scores was applied. Medical history and demographic data, preoperative FIGO stage, PET/CT findings, CT findings final pathology diagnosis, type of surgery and perioperative details were reviewed. Intraclass correlation coefficient was calculated to compare the PCI obtained preoperatively in PET/CT and CeCT with the PCI obtained in the final surgery.

Results The interclass correlation coefficient in the global cohort of patients compared to the PCI calculated intraoperatively was 0.867 for CeCT and 0.807 for PET-CT. Regarding the prediction of complete cytoreduction, the area under the curve in the CeCT was 0.659 and 0.690 in the PET-CT.

Conclusion Despite the small sample size, this initial study highlights that CeCT is more effective in calculating PCI preoperatively, however, PET-CT is better at predicting complete cytoreduction. Further validation in larger series is needed.

2022-RA-1622-ESGO MALIGNANT BRENNER TUMOR OF THE OVARY: CASE SERIES OF ONE SINGLE INSTITUTE

1Amani Jellali, 1Malek Bouhani, 1Takoua Chalouati, 1Saïda Sahri, 1Ines Houissa, 2Ghada Sahraoui, 1Riadh Chargui, 1Khaled Rahal. 1Department of surgical oncology, Salah Azaiez Institute, Tunisia, Tunisia; 2Pathology department, Salah Azaiez Institute, Tunis, Tunisia

10.1136/ijgc-2022-ESGO.758
Abstracts

EFFECT OF BEVACIZUMAB AND COMPLETE CYTOREDUCTION SURGERY IN ADVANCED LOW GRADE SEROUS OVARIAN CANCER: A SECONDARY ANALYSIS OF MITO 22

1Lucia Musacchio, 2Margherita Turninetti, 3Michele Bortoletti, 4Laura Arendre, 5Daniela Calfano, 6Valentina Turninetti, 7Gennaro Corno, 8Carmela Pisano, 9Giorgio Valabrega, 10Claudia Marchetti, 11Sabrina Chiara Cecere, 12Stefano Greggi, 13Francesco Raspagliesi, 14Francesco Perone, 15Anna Fagotti, 16Domenica Lorusso, 17Giovanni Scambia, 18Sandro Pignata, 19Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; 20University of Torino at Ordine Mauriziano, Torino, Italy; 21Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; 22Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy; 23Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy; 24Department of Oncology, University of Torino at Ordine Mauriziano Hospital, Turin, Italy; 25Gynecologic Oncology Institute Tumori Giovanni Paolo II – IRCCS, Bari, Italy; 26Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; 27Department of Oncology, University of Torino at Ordine Mauriziano, Torino, Italy; 28Gynecologic Oncology Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy; 29Gynecologic Oncology Unit, Fondazione Istituto Nazionale Tumori, IRCCS, Milan, Italy; 30Michele Bartoletti, 31Laura Arenare, 32Margherita Turinetto, 33Michele Bartoletti, 34Laura Arenare, 35Giovanni Scambia, 36Sandro Pignata.

Introduction/Background Malignant Brenner tumors (MBT) of the ovary are rare disease; representing 1.5% of all ovarian cancers and 3.5% of Brenner tumors. They carry a poor prognosis. They generally affect women during the perimenopausal and postmenopausal periods. The aim of this study is to report our experience in the treatment of MBT of the ovary, to better characterize this disease.

Methodology A retrospective case series involving 5 patients diagnosed with MBT of the ovary and treated between 2006 and 2020.

Results The mean age of our patients was 54.1 years. Four patients were in the menopause period. The tumor was staged as IC in one case, IIc in one case and IIC in three cases of FIGO classification. All women conducted surgery followed by adjuvant chemotherapy. Four patients underwent a loco-regional recurrence that occurred respectively after 9, 11 and 13 months in three patients. The treatment was based on chemotherapy, combined with surgery in one case. Two patients presented distant metastasis. The treatment consisted of chemotherapy and surgery. One patient of them died after surgery from massive pulmonary embolism. The mean follow up period was 39.5 months.

Conclusion The treatment approach of MBT of the ovary is not well established since its scarcity and poor prognosis. Thus, more case series and meta-analysis should be conducted.

2022-RA-1633-ESGO CAN A MORPHOLOGICAL DESCRIPTION OF THE PERITONEAL CARCINOMATOSIS IN ADVANCED OVARIAN CANCER ADD PROGNOSTIC INFORMATION? SYSTEMATIC ANALYSIS IN 1686 PATIENTS

1Sara Nasser, 2Aygun Babayeva, 3Isvana Elena Braicu, 4Rolf Richter, 5ESA Bilir, 6Radislav Chekerov, 7Mustafa Zelal Muallem, 8Klaus Pietzner, 9Gülhan Inç, 10Jalid Selhouli.

Introduction/Background Peritoneal carcinomatosis in ovarian cancer is frequent and generally associated with higher stage and poorer outcome. The clinical features of peritoneal carcinomatosis are diverse and their relevance for surgical and long-term outcome remains unclear. We conducted this prospective study to describe intraoperatively the different features of peritoneal carcinomatosis (PC) and to correlate them with clinicopathological features and survival outcomes.

Methodology We performed systematic analysis of all patients with documented intraoperative PC and a primary diagnosis of epithelial ovarian, tubal, or peritoneal cancer from January 2001 to September 2018. All data were evaluated by using the systematic tumour bank tool. Specific PC features included texture (soft-hard), consistency (coarse-fine or both), wet vs dry, and localization (diffuse-local). The PC characteristics were then evaluated for correlation with age, FIGO-stage, tumour histology, lymph-node involvement, tumour grade, and presence of residual tumour. Moreover, the influence of PC characteristics on overall-survival(OS) and progression-free survival (PFS) was analysed.

Results 1686 patients with PC and primary epithelial ovarian cancer were included. Majority of the patients had diffuse PC (73.9%). The majority of PC were fine in texture (55.3%) and hard in consistency (87.4%). 27.6% of patients had dry PC. Diffuse localization of PC was significantly associated with